Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
7 juni aandeelhoudersvergadering.
Ben benieuwd, ik hou ze vast!
Denk dat we niet echt veel horen pietje, denk wel uitsluitsel over het dividend uitbetalen, en ik hoop dat ze nog een leuke opdracht binnen gesnoept hebben, fijn weekend allemaal
Wel altijd een trading update ! Zou de omzet waar ze zicht hebben al boven de 21.5-22 mij. liggen lijkt me dat, de weg omhoog zeker weer hervat wordt> We zullen zien
Sopheon ITEA3 Medolution Google Assistant Patient Records Demonstratorwww.youtube.com/watch?v=ze5ZOV4edLU
Koers zit weer in een stijgende lijn richting de trading update, vandaag 4 maal 5000 aandelen over de toonbank, iemand een idee wat we kunnen verwachten overmorgen?
Ik heb vandaag een verkoop order van 1000stuk tegen 8,80 opgegeven, maar niks gebeurd bij mijn broker(rabo) iemand vaker meegemaakt?
Mijn verwachting is een goede trading update mocht de visible 30% hoger liggen dan vorig jaar 17,5 miljoen *1,3 dus 23 miljoen bijna de totale omzet van 2016 dab kan het weer hard omhoog gaan! Bij meer dan 21-22milj omhoog. Ik snap alleen niet van de verkopen en kopen de laatste tijd! lijkt wel een op en neer geschuif. Zou bijna verwachten dat iemand een melding moet gaan maken dat hij of zij minder aandelen hebben of iemand de 3% overschrijdt. Maarja wie ben ik. En inderdaad, al dagen 0rders van 5000 voor ongeveer 880. En dan deze nog vandaag 09:25:36 05-Jun-2018 880.50 GBX 19,605 172,622.02 Off-book SINT LRGS Lijkt me geen gewone man die dit doet. En Dan gaan ze nog tot 1 miljoen aandelen zelf inkopen(gaat rivermore cashen?) Vele vragen nog geen antwoorden hopelijk donderdag meer antwoorden. Maar ik verwacht een goede update. Wat ik al heb gezegd na de halfjaar cijfers 15 euro. Dit is geen beleggingsadvies maar mijn verwachting. Met toch wat vragen en met die rare kopen en verkopen ook een beetje onzekerheid. Trinko
Heb je al wat gehoord paiser? Misschien als je je verkooporder aanbied tegen bid price
Nee is nog steeds 'lopend' als ik bij de rabo kijk. Misschien dat investing.thisismoney.co.uk/trades/SP... en dan 5 jun 17:08:02 'm is, wacht het rustig een dagje af.
Your Partner for Innovation Performance™ Go to... Sopheon Logo Go to... AGM Statement AGM Statement At today’s Annual General Meeting of Sopheon, the international provider of software and services that help organizations generate more revenues and profits from new products, the Board will give shareholders an update and review of the business. In conjunction with a truly exceptional financial performance in 2017, we continue to advance our strategy to be the world’s leading provider of enterprise-class innovation management solutions. Our vision has consistently led the market, and this is a market that continues to evolve and demonstrate considerable growth. We delivered a very strong finish to last year, resulting in all the Group’s headline financial measures exceeding market expectations by a significant margin. Revenues rose to $28.5m from $23.2m in 2016. On the back of an already strong increase in profitability in 2016, EBITDA last year reached $8.0m, up from $5.6m the year before, and profit before tax was $5.1m, compared to $3.0m the year before. Alongside a realignment of our debt position, this resulted in net assets rising to $18.6m from $10.4m the year before, and net cash rising to $9.5m from $4.2m. Both volume and average value of license transactions increased compared to the year before. Towards the end of 2017 we signed substantial deals with two industry leading, blue chip companies in the USA and in Germany and we are now in the process of implementing our Accolade® solution globally in both cases. Such customers further validate the momentum and acceptance of Accolade as an enterprise platform within the largest and most influential corporations in the world. We saw more acceptance of our SaaS (Software as a Service) offering, with three new SaaS customers signed last year, and our recurring revenue base improved to over $12m by the end of the year compared to just under $10m the year before. Sopheon’s market differentiation continues to be validated. Sopheon is the only vendor recognized in three different Gartner Market Guides — for Strategy Execution Management Software; Innovation Management Tools; and Strategy & Innovation Roadmapping Tools – as well as in its Magic Quadrant for Project Portfolio Management Worldwide. In our view, the capabilities called for in all of these respective reports are required to deliver on the promise of connecting strategic planning and operational execution. In addition, Sopheon was named a Leader in the 2017 Forrester Wave™: Strategic Portfolio Management Tools. Further recent market validation was recognition by Consumer Goods Technology magazine, naming Sopheon as “Best in Category” in new product development and introduction as voted by readers. Collectively, these are major strategic milestones in establishing the credentials of both the Company and our market. In order to deliver on our growth strategies as described in our annual report, we are executing on ambitious investment plans across multiple functional areas to scale for growth for 2018 and beyond. Where appropriate, we are also open to consideration of targeted M&A opportunities if consistent with our goals and focused investment criteria. Alongside strategic initiatives, we remain highly driven by revenue and profit objectives, and to stand behind this ambition we have proposed a maiden dividend, to be put to the Company’s shareholders at today’s meeting. Remaining on the corporate theme, we were delighted with the success of our oversubscribed secondary placing completed in mid-May, which expanded our institutional shareholder base, and we are grateful for the support and demand shown by certain blue chip institutional investors for the Company’s shares. Outlook The positive momentum has continued this year, and we are signing additional new business, which in turn is underpinning the performance for the year. Full year revenue visibility for 2018 from contracted business and recurring revenue streams is now up 34% at $23.5m, compared to $17.5m at this time last year – an all-time high for our mid-year AGM report. This includes the effect of several perpetual license deals and major services extensions, as well as a further major SaaS deal closed during the current quarter. The Board continues to be confident and enthusiastic about the prospects of the Company, the outturn for the year and the opportunity to continue to deliver on our vision. For Further Information Contact: Barry Mence, Chairman Arif Karimjee, CFO Sopheon plc + 44 (0) 1276 919 560 Carl Holmes / Giles Rolls (corporate finance) Alice Lane (corporate broking) finnCap + 44 (0) 20 7220 0500 The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014. About Sopheon Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon’s Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon’s solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. Print Friendly, PDF & EmailPrint June 7th, 2018 Share This Story, Choose Your Platform! FacebookTwitterLinkedinGoogle+Email INVESTORS Board of Directors Corporate Information Financial Releases Financial Reports Investors FAQs Analysts & Research Request Investor Info NEWSLETTER Register Here WEBINARS & VIDEOS Upcoming Webinar: Innovation Overdrive: Align the Moving Parts with Speed and Agility Expanding Sopheon’s Footprint and Seizing Growth Opportunities #DigInnovation: Enabling companies to transform with speed and agility RECENT POSTS AGM Statement Upcoming Webinar: Innovation Overdrive: Align the Moving Parts with Speed and Agility How to Assign the Right Metrics to Drive Portfolio Performance RECENT TWEETS #TeamSopheon has junior to senior level software engineer positions open ow.ly/RrgT30knjBb pic.twitter.com/IYOxgzUNPq 6 hours ago ? “ World Environment Day 2018” by @covestro twitter.com/i/moments/1003… #TeamAccolade 1 day ago RSS Feeds | Sitemap | Privacy | Legal | Contact Us :: Copyright 2018 Sopheon. All Rights Reserved RssTwitterYouTubeGoogle+LinkedinFacebook This site uses cookies to store information on your computer. Some of these cookies are essential to make our site work and others help us to improve by giving us some insight into how the site is being used. Information will be used in accordance with our Privacy Policy Accept Recommended Settings Necessary Cookies Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences. Analytic Cookies Enable Disable Analytic cookies help us to improve our website by collecting and reporting usage information. Advertising Cookies Enable Disable Advertising cookies track visitors across websites so targeted ad content can be displayed based on individual users interests. Preference Cookies Enable Disable Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
Groei van 34 procent, dit is wat je bedoelde trinko;-))))
Weinig echt nieuws te melden zo te lezen, behalve: recurring revenue base improved to over $12m by the end of the year compared to just under $10m the year before. Full year revenue visibility for 2018 from contracted business and recurring revenue streams is now up 34% at $23.5m, compared to $17.5m at this time last year – an all-time high for our mid-year AGM report. ...en dat laatste is natuurlijk wel weer heel goed nieuws.
Juist Gartje dit is meer dan ze in heel 2016 als omzet hadden Trinko
Zeer goede cijfers, ben benieuwd of de koers gaat exploderen
Weet niet hoe de markt er op gaat reageren maar in deze onzekere tijd met die pipo in Amerika vind ik dit een prima update, de groei gaat maar door en door!!
we are grateful for the support and demand shown by certain blue chip institutional investors for the Company’s shares. Vond ik ook wel aardig!!
Die betaalde niet voor niets 986 per aandeel
Zijn er meerdere he! Investors!
Ben benieuwd wat de koers gaat doen!
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
860,01
-0,62%
EUR/USD
1,0655
+0,11%
FTSE 100
7.895,85
+0,24%
Germany40^
17.714,20
-0,13%
Gold spot
2.392,50
0,00%
NY-Nasdaq Composite
15.282,01
-2,05%
Stijgers
Dalers